AI in Healthcare 2025

Tern plc

The year 2025 marked a significant shift in the integration of artificial intelligence into healthcare, as the technology moved from experimental phases into active use across clinical and commercial settings. AI, once viewed as a long-term prospect, began delivering practical benefits, with healthcare organisations adopting it to streamline operations, enhance patient communication and improve medical outcomes.

Throughout the year, generative AI was deployed more widely in hospitals, clinics and pharmaceutical companies. Clinical teams used it to produce care plans and patient notes in real time, reducing time spent on documentation and allowing more focus on decision-making and patient care. Predictive AI was applied to flag potential hospital readmissions and other risks before they materialised, contributing to efficiency gains and better patient outcomes. At the same time, AI-generated, multi-language patient education materials helped address gaps in communication, particularly for underserved populations.

In the pharmaceutical and healthcare marketing sectors, data intelligence and targeting technologies helped refine how companies engaged with both clinicians and patients. Rather than relying on broad messaging, marketers used AI-driven insights to tailor communications more precisely, increasing engagement and improving return on investment.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search